Synonyms: N-tert-Butyl isoquine
Compound class:
Synthetic organic
Comment: GSK369796 is a 4-aminoquinoline antimalarial compound that was synthesised using amodiaquine as the template molecule [3].
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Guide to Malaria Pharmacology Comments |
GSK369796 was developed by academics at Liverpool as part of a public-private partnership managed by the Medicines for Malaria Venture (MMV) [3]. This research collaboration, utilised the 4-aminoquinoline scaffold of amodiaquine to design and synthesise derivatives active against both chloroquine-susceptible and chloroquine-resistant P. falciparum strains. Potential Target/Mechanism Of Action: As the precise MOA of GSK369796 is not yet known, we do not have a molecular target for this compound. It is thought that GSK369796 has a similar MOA to chloroquine, killing the malaria parasite by causing a build up of toxic heme by inhibiting the enzyme that normally converts it to non-toxic haemozoin [1]. |